Arecor Therapeutics PLC EXCLUSIVE COLLABORATION WITH INTAS PHARMACEUTICALS (9037K)
07 September 2021 - 4:00PM
UK Regulatory
TIDMAREC
RNS Number : 9037K
Arecor Therapeutics PLC
07 September 2021
Arecor Therapeutics plc
("Arecor" or the "Group")
EXCLUSIVE FORMULATION COLLABORATION WITH INTAS PHARMACEUTICALS
LTD
Cambridge, UK, 07 September 2021. Arecor Therapeutics plc (AIM:
AREC) , the biopharmaceutical group advancing today's therapies to
enable healthier lives, today announces that it has signed a
formulation agreement with Intas Pharmaceuticals Ltd ("Intas").
Under this agreement, Arecor will use its proprietary
formulation technology platform Arestat(TM) to develop a
differentiated product for Intas. The new product formulation
supports improved usability for the patient compared to current
marketed products and in particular facilitates home use outside of
a healthcare environment. Intas will fund the development work and
has the option to acquire the global rights to the new proprietary
formulation and associated Intellectual Property under a technology
licensing model (with associated potential milestone and royalty
payments) to further develop and commercialise the product. Accord
Healthcare, an affiliate of Intas, will, upon successful
completion, promote this product across all major markets.
Arestat(TM) is an innovative and proprietary formulation
technology platform which enhances the properties of therapeutic
proteins, peptides and vaccines. Arecor applies the Arestat(TM)
technology to deliver superior reformulations of existing products
as well as improving properties of new products in development.
Sarah Howell, Chief Executive Officer of Arecor, said: " We are
delighted to be working with Intas. Our Arestat(TM) technology has
the potential to deliver to Intas a new formulation to support
development of a stable liquid product that meets patient needs.
This collaboration recognises our capabilities in product
formulation, overcoming the complex challenges associated with
developing these products. Intas who are a new development partner
for Arecor, further strengthens our portfolio with major
pharmaceutical companies and demonstrates how our formulation
expertise can bring enhanced products to market for partners that
simplify care and improve medicine management."
"The collaboration with Arecor demonstrates our emphasis on
value addition towards strengthening our portfolio to provide
improved therapeutic options for patients and healthcare in
general", said Mr. Binish Chudgar, Vice Chairman of Intas
Pharmaceuticals. "We are committed to improving access to
innovation-driven value-added medicines to make a real difference
in patient's life".
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 (MAR)
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
group transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
About Intas
Intas Pharmaceuticals Ltd. is a leading vertically integrated
pharmaceutical company based in Ahmedabad, India, having end-to-end
capabilities of formulation development, manufacturing and
marketing along with backward integration of APIs. Intas has more
than 16,000 employees, sells products in more than 85 countries and
has 14 manufacturing sites worldwide. The Intas group's revenues
amounted to USD 2.1 bn in FY 2020 and the compounded annual growth
rate of Intas' revenues has exceeded 25% in the past 10 years.
For more information, please visit www.intaspharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRLFMRTMTAMBLB
(END) Dow Jones Newswires
September 07, 2021 02:00 ET (06:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2023 to Apr 2024